Vaccine Choice Canada Hepatitis B - Disease & Vaccine Information

Hepatitis B

Hepatitis B is an infection that infects the liver. The disease can cause mild illness lasting a few weeks, or in rare cases can lead to a serious lifelong illness. Hep B is spread through the exchange of bodily fluids from sex and IV drug use. Given that our newborns and infants are not engaged in these high-risk behaviours, the risk of contracting Hep B is exceedingly rare. The only legitimate risk to infants is birth from a mother with Hep B. Every mother who receives prenatal care is tested for Hep B. In spite of the this, Health Canada recommends Hep B vaccination for our infants. Some provinces (NB, NU, NT) administer Hep B vaccination on the first day of life.

The Vaccine

The Hep B vaccine is a bioengineered vaccine, meaning that its DNA has been genetically modified. The vaccine manufacturers claim this renders the vaccine incapable of infecting the recipient though this has not been established.
The vaccine requires the use of aluminum to trigger an immune response.
In the 1980’s the vaccine was recommended primarily for IV drug users, people with multiple partners, and for refugees from countries where Hep B is common.
In 1991, the CDC changed their recommendation from vaccinating only those people at risk to vaccinating every infant. They justified this change in policy because public health officials could not persuade high risk adults to get the vaccine.
Health Canada recommends 3 doses of hepatitis B vaccine by 6 months of age, regardless of maternal infection status.

Considerations for the Vaccine Decision

The question that ought to be considered is – What possible benefit will the vaccines offer infants and children given they are not at risk of contracting Hep B?
The protection offered by the vaccine wanes over time.
There is no evidence demonstrating that vaccine induced immunity to Hep B in infancy will persist to adulthood when individuals may be at risk of infection due to occupation or lifestyle choices.
The vaccine contains 250 micrograms of aluminum per dose. Aluminum is a known neurotoxin.
The maximum recommended safe dosage of aluminum for a newborn is 10 – 15 micrograms.
Our infants are receiving 16 – 20 times the safe dosage of aluminum in each Hep B vaccine.
Giving the Hep B series of vaccines to newborns exposes them to toxic levels of aluminum, and also fails to give them lasting protection against Hep B.
As of March 31, 2023, there have been more than 102,881 adverse events reported to the Vaccine Adverse Events Reporting System in connection with Hepatitis B containing vaccines. Nearly 56% (57,336) of serious Hepatitis B vaccine-related adverse events occurred in children under three years old, with over 70% (1,711) of deaths occurring in children under three years of age.[20]
The incidence of serious Hep B vaccine related adverse events significantly exceeds the number of childhood infections each year.
A US HHS study acknowledged that less than 1% of vaccine adverse events are reported.[21]
The safety of the Hep B vaccine has not been proven against a true placebo.
Individuals who recover from an acute hepatitis B infection and clear the virus are immune for life.

For more information: https://www.nvic.org/disease-vaccine/hepatitis-b

References

[20] https://www.nvic.org/disease-vaccine/hepatitis-b/quick-facts

[21] Vaccine Adverse Events Reporting System – https://digital.ahrq.gov/sites/default/files/docs/publication/r18hs017045-lazarus-final-report-2011.pdf

Vaccine Product Monographs

DTaP-HB-IPV-Hib (diphtheria, tetanus, pertussis, hepatitis B, polio, Haemophilus influenza)

Product: Infanrix Hexa (GSK)

Product Monograph: https://ca.gsk.com/media/6247/infanrix-hexa.pdf (35 pages)

Patient Information sheet:

Manufacturer website: https://ca.gsk.com/en-ca/products